In an era of increased telemedicine:
Augment your Risk Assessment of Hepatocellular Carcinoma
with FDA cleared serum biomarkers AFP-L3 and DCP

AFP-L3 and DCP are *in vitro* diagnostic serum biomarkers

**AFP-L3:*** Lectin-reactive alpha-fetoprotein  
**DCP:*** Des-gamma-carboxy prothrombin

**AFP-L3**% ≥ 10%: Associated with 10.6-fold increased risk of developing HCC

**DCP** ≥ 7.5 ng/mL: Associated with 4.8-fold increased risk of developing HCC

Both biomarkers are commercially available through major US reference labs and CMS reimbursed

---

**Overview of Intended Uses (See package inserts):**
The μTASWako AFP-L3 and DCP test systems are in vitro devices that consist of reagents used with the μTASWako i30 immunoanalyzer to quantitatively measure, by immunochromatographic techniques, AFP-L3% and DCP in human serum. Both devices are intended for IVD use as aids in the risk assessment of patients with chronic liver disease for development of HCC in conjunction with other laboratory findings, imaging studies and clinical assessment.

**AFP-L3 Positive**

<table>
<thead>
<tr>
<th>Results from a study showing the complementary use of AFP-L3, DCP and AFP from 74 patients with HCC diagnosis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>90.5% (87/74) of the patients with HCV-related cirrhosis and HCC diagnosis demonstrated at least one elevated biomarker at time of diagnosis. The use of AFP alone would not have identified 29.7% (22/74) of patients at risk of development of HCC.*</td>
</tr>
<tr>
<td><strong>Biomarker</strong></td>
</tr>
<tr>
<td><strong>AFP-L3</strong> DCP and AFP</td>
</tr>
<tr>
<td><strong>AFP (alone)</strong></td>
</tr>
</tbody>
</table>

* FUJIFILM Wako Diagnostics does not have a claim for the use of the AFP Serum Biomarker in the risk assessment of patients with chronic liver disease for development of HCC and has not established a threshold for AFP.

**AFP-L3**% ≥ 10%: Associated with 10.6-fold increased risk of developing HCC

**DCP** ≥ 7.5 ng/mL: Associated with 4.8-fold increased risk of developing HCC

* FUJIFILM Wako Diagnostics does not have a claim for the use of the AFP Serum Biomarker in the risk assessment of patients with chronic liver disease for development of HCC and has not established a threshold for AFP.

---

**Intestinal alterations in PSC pathogenesis**

---

**Hepatology**

**Journal of the American Association for the Study of Liver Diseases**

**VOLUME 72 | SEPTEMBER 2020 — PAGES 791-1162**

---

**IN THIS ISSUE:**

**COVID-19 and acute liver injury**

Assessing genetic determinants of cirrhosis and HCC in fatty liver disease

Cutting the (de novo) fat? Acot9 as potential target for NAFLD